Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMZ2G69)

Drug Name
Navicixizumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 1 [1]
Fallopian tube cancer 2C74 Phase 1 [2]
Metastatic colorectal cancer 2B91 Phase 1 [2]
Ovarian cancer 2C73 Phase 1 [1]
Peritoneal cavity cancer 2C51.Z Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMZ2G69

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Delta-like protein 4 (DLL4) TTV23LH DLL4_HUMAN Not Available [1]
Vascular endothelial growth factor A (VEGFA) TTOHSBA VEGFA_HUMAN Not Available [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 8.544 6.927 7.253 7.839
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Colorectal cancer
ICD Disease Classification 2B91.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 3.61E-01 0.15 0.47
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)